MYOM2 and Miyoshi myopathy: In the clinical practice of MM in patients being treated with daratumumab/isatuximab, the use of the HYDRASHIFT/HYDRASYS showed good performance, exhibiting higher sensitivity and specificity, providing accurate CR assessment, correctly identifying serum free‐κ in a patient with renal impairment, and detecting small M‐proteins upon relapse.